5 active not recruiting, 3 completed, 3 recruiting. 11 Phase 3, 1 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 3 | 11 | Active not recruiting 5, Completed 3, Recruiting 3 |
| Phase 2 | 1 | Active not recruiting 1 |
Follow mitapivat: new trials by email Literature Review of mitapivat trials Research Report on mitapivat
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Study to Investigate the Efficacy, Pharmacokinetics, and Safety of Mitapivat in Pediatric Participants With Transfusion-Dependent Alpha- or Beta-Thalassemia (α- or β-TDT) Mitapivat Matched Placebo, Mitapivat - Transfusion-dependent Alpha-Thalassemia, Transfusion-dependent Beta-Thalassemia | Phase 3 | Recruiting | Agios Pharmaceuticals, Inc. | 54 | 2026-09-24 | 2026-10-29 |
| A Study to Investigate the Efficacy, Pharmacokinetics, and Safety of Mitapivat in Pediatric Participants With α- or β-Non-Transfusion-Dependent Thalassemia Mitapivat, Placebo Matching Mitapivat - Non-Transfusion-dependent Alpha-Thalassemia, Non-Transfusion-dependent Beta-Thalassemia | Phase 3 | Recruiting | Agios Pharmaceuticals, Inc. | 45 | 2026-09-01 | 2026-10-28 |
| A Study to Investigate the Effect of Mitapivat on Transfusion Burden in Subjects With Sickle Cell Disease (SCD) Mitapivat Matched Placebo, Mitapivat - Sickle Cell Disease | Phase 3 | Recruiting | Agios Pharmaceuticals, Inc. | 159 | 2026-07-21 | 2026-10-28 |
| A Study to Evaluate the Efficacy and Safety of Mitapivat in Pediatric Participants With Pyruvate Kinase Deficiency (PKD) Who Are Regularly Transfused, Followed by a 5-Year Extension Period Mitapivat, Mitapivat-matching placebo - Pediatric Pyruvate Kinase Deficiency, Pediatric Hemolytic Anemia | Phase 3 | Active not recruiting | Agios Pharmaceuticals, Inc. | 49 | 2022-06-08 | 2026-10-28 |
| A Study to Evaluate the Efficacy and Safety of Mitapivat in Pediatric Participants With Pyruvate Kinase Deficiency (PKD) Who Are Not Regularly Transfused, Followed by a 5-Year Extension Period Mitapivat, Mitapivat-matching placebo - Pediatric Pyruvate Kinase Deficiency, Pediatric Hemolytic Anemia | Phase 3 | Active not recruiting | Agios Pharmaceuticals, Inc. | 30 | 2022-06-06 | 2026-10-28 |
| A Study Evaluating the Efficacy and Safety of Mitapivat (AG-348) in Participants With Sickle Cell Disease (RISE UP) Mitapivat, Mitapivat-matching placebo - Sickle Cell Disease | Phase 2 / Phase 3 | Active not recruiting | Agios Pharmaceuticals, Inc. | 286 | 2022-02-11 | 2026-10-26 |
| A Study Evaluating the Efficacy and Safety of Mitapivat in Participants With Non-Transfusion-Dependent Alpha- or Beta-Thalassemia (α- or β-NTDT) Placebo Matching Mitapivat, Mitapivat - Non-Transfusion-dependent Alpha-Thalassemia, Non-Transfusion-dependent Beta-Thalassemia | Phase 3 | Active not recruiting | Agios Pharmaceuticals, Inc. | 194 | 2021-12-20 | 2026-10-30 |
| A Study Evaluating the Efficacy and Safety of Mitapivat in Participants With Transfusion-Dependent Alpha- or Beta-Thalassemia (α- or β-TDT) Placebo Matching Mitapivat, Mitapivat - Transfusion-dependent Alpha-Thalassemia, Transfusion-dependent Beta-Thalassemia | Phase 3 | Active not recruiting | Agios Pharmaceuticals, Inc. | 258 | 2021-11-30 | 2026-10-28 |
| Extension Study of AG-348 in Adult Participants With Pyruvate Kinase Deficiency Previously Enrolled in AG-348-006 or AG348-C-007 Mitapivat - Pyruvate Kinase Deficiency | Phase 3 | Completed | Agios Pharmaceuticals, Inc. | 90 | 2019-03-21 | 2025-11-18 |
| A Study to Evaluate Efficacy and Safety of AG-348 in Not Regularly Transfused Adult Participants With Pyruvate Kinase Deficiency (PKD) Placebo, AG-348 - Pyruvate Kinase Deficiency, Anemia, Hemolytic | Phase 3 | Completed | Agios Pharmaceuticals, Inc. | 80 | 2018-08-09 | 2022-05-24 |
| A Study Evaluating the Efficacy and Safety of AG-348 in Regularly Transfused Adult Participants With Pyruvate Kinase Deficiency (PKD) AG-348 - Pyruvate Kinase Deficiency, Anemia, Hemolytic | Phase 3 | Completed | Agios Pharmaceuticals, Inc. | 27 | 2018-06-26 | 2022-01-04 |
Pyruvate Kinase Deficiency of Red Cells (5) · Anemia (2) · Anemia, Hemolytic (2) · Anemia, Sickle Cell (2) · Hematologic Diseases (2) · Metabolic Diseases (2)
Agios Pharmaceuticals, Inc. (11)
United States (11) · Canada (8) · Netherlands (8) · France (7) · United Kingdom (7) · Denmark (6) · Germany (6) · Italy (6) · Spain (6) · Turkey (Türkiye) (6) · Brazil (5) · Thailand (5) · Switzerland (4) · Lebanon (3) · Saudi Arabia (3)
PMID 31974203, PMID 36594181, PMID 38330179, PMID 35417638, PMID 35988546, PMID 37254256, PMID 37934880, PMID 37943362, PMID 39644907, PMID 40544857, PMID 41809202, PMID 42721980, PMID 42913682
2025 (2), 2017 (1), 2018 (1)